MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Does Stopping GLP-1 Treatment Really Mean for Your Heart

1 hour ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Does High Short Interest Really Mean for a Stock

2 weeks ago

Is the GLP-1 Price War Escalating, and What Does it Mean for Eli Lilly

3 weeks ago

What Does a Director's Big Bet on CMTG Really Mean

3 weeks ago

What Does Pony.ai's Shenzhen Breakeven Really Mean for Investors

2 weeks ago

Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says

Risks of heart attack, stroke, and death increase for Type 2 diabetes patients following short gaps in GLP-1 treatment, according to new research.

GLP

Stock News•2 weeks ago

Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

Orchestra BioMed announced two presentations at the THT and CRT 2026 Meetings highlighting AVIM Therapy's potential impact on hypertensive heart disease and heart failure patients.

CRT

Stock News•3 weeks ago

Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome

Aardvark Therapeutics voluntarily paused its Phase 3 HERO trial evaluating ARD-101 for hyperphagia in Prader-Willi Syndrome patients. The pause affects the ongoing randomized, double-blind, placebo-co...

HERO

Stock News•2 months ago

Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?

Novo Nordisk's FDA-approved Wegovy pill is the first oral GLP-1 weight loss therapy, expected to revive momentum and reshape competition starting in 2026.

NVO